Aldeyra Therapeutics Innovates Treatments for Immune-Mediated Diseases with Unique Drug Development Approach

### Aldeyra Therapeutics Advances Innovative Approaches to Treat Immune-Mediated Diseases

Aldeyra Therapeutics, Inc., a biotechnology firm focused on innovative therapies for immune-mediated and metabolic diseases, highlights its unique approach to drug development. The company emphasizes the modulation of protein systems, which marks a departure from traditional methods that target individual proteins. This strategy aims to optimize multiple biological pathways while minimizing toxicity, a significant consideration in the development of therapeutic agents. By targeting reactive aldehyde species (RASP), Aldeyra aims to address complex conditions with a broader pharmacological impact.

Within its promising product pipeline, Aldeyra is developing several RASP modulators, including ADX-629, ADX-248, ADX-743, ADX-631, and ADX-246. These agents are positioned to tackle both systemic and retinal immune-mediated and metabolic diseases. Among the notable candidates is reproxalap, which is currently under investigation for its efficacy in treating dry eye disease and allergic conjunctivitis. This late-stage candidate highlights Aldeyra's commitment to addressing prevalent conditions that significantly affect patient quality of life. Additionally, ADX-2191, a novel formulation of intravitreal methotrexate, is being explored for its potential in treating retinitis pigmentosa, a hereditary disease that leads to vision loss.

Aldeyra's ongoing mission is to discover and develop therapies that could profoundly impact patients facing these challenging diseases. The company continues to build on its innovative platform and aims for advancements that not only provide symptomatic relief but also address the underlying mechanisms of these immune-mediated conditions. With a focus on research and development, Aldeyra is well-positioned to contribute to the future of therapeutic options available for patients suffering from immune-mediated and metabolic diseases.

In addition to its research efforts, Dr. Todd C. Brady, the company's President and CEO, is set to engage with the investment community during a fireside chat at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference on February 11, 2025. This virtual event provides an opportunity for stakeholders to gain insights into Aldeyra’s strategies and future directions. The session will be accessible via a live webcast, with an archived version available for 90 days, ensuring that interested parties can stay informed about the company’s developments.

Aldeyra Therapeutics continues to forge ahead in an evolving biotechnology landscape, focusing on therapies that offer hope to those affected by complex immune-mediated and metabolic diseases. By prioritizing innovative approaches that address multiple pathways, the company solidifies its role as a key player in the development of next-generation treatments.